First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult
Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
First Ascent Biomedical announced findings from ongoing clinical
studies conducted in partnership with Florida International University, examining the company’s
Functional Precision Medicine (FPM) platform in adult and pediatric patients with difficult-to-treat
cancers. The study findings were presented during poster sessions at the 2024 American Society of
Clinical Oncology (ASCO) annual meeting in Chicago.